{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:39:55Z","timestamp":1771011595205,"version":"3.50.1"},"reference-count":265,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Cancer Institute of the National Institute of Health","award":["1R21CA185236-01"],"award-info":[{"award-number":["1R21CA185236-01"]}]},{"name":"National Cancer Institute of the National Institute of Health","award":["1 R33 CA212968-01"],"award-info":[{"award-number":["1 R33 CA212968-01"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.addr.2017.06.010","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T12:32:35Z","timestamp":1497616355000},"page":"285-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Drug discovery and therapeutic delivery for the treatment of B and T cell tumors"],"prefix":"10.1016","volume":"114","author":[{"given":"Regan","family":"Stephenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2017.06.010_bb0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1586\/eci.10.36","article-title":"Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease","volume":"6","author":"Bewtra","year":"2010","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.addr.2017.06.010_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0015","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.06.010_bb0020","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0040","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jcp.2010.083832","article-title":"CDKN1B\/p27 expression in peripheral T cell lymphoma not otherwise specified","volume":"64","author":"Gazzola","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.addr.2017.06.010_bb0050","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2013.11.009","article-title":"Management of T-cell lymphomas: overcoming challenges and choosing the best treatment","volume":"51","author":"Reddy","year":"2014","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2017.06.010_bb0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2017.06.010_bb0070","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/cncr.29258","article-title":"The past, present, and future of cancer incidence in the United States: 1975 through 2020","volume":"121","author":"Weir","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2017.06.010_bb0075","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2017.06.010_bb0080","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.coi.2008.06.007","article-title":"Terminal sugars of Fc glycans influence antibody effector functions of IgGs","volume":"20","author":"Raju","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.addr.2017.06.010_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2017.06.010_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fonc.2014.00082","article-title":"Antibody therapy for pediatric leukemia","volume":"4","author":"Vedi","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc[gamma] receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2017.06.010_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd3365","article-title":"Advances in the assessment and control of the effector functions of therapeutic antibodies","volume":"10","author":"Jiang","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0105","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1517\/14712598.7.9.1401","article-title":"Antibody therapeutics: isotype and glycoform selection","volume":"7","author":"Jefferis","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2017.06.010_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/35018508","article-title":"The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex","volume":"406","author":"Sondermann","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0115","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.06.010_bb0120","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.06.010_bb0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jim.2005.08.009","article-title":"IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides","volume":"306","author":"Niwa","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.addr.2017.06.010_bb0130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/bit.20777","article-title":"Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II","volume":"93","author":"Ferrara","year":"2006","journal-title":"Biotechnol. Bioeng."},{"issue":"12","key":"10.1016\/j.addr.2017.06.010_bb0135","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0140","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1535-7163.MCT-12-0278","article-title":"Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells","volume":"11","author":"Chang","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2017.06.010_bb0145","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Czuczman","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0150","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0155","doi-asserted-by":"crossref","first-page":"e44482","DOI":"10.1371\/journal.pone.0044482","article-title":"An Il12-Il2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of Nk and T cells for an anti-tumor attack","volume":"7","author":"Jahn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.06.010_bb0160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjh.12630","article-title":"Phase IA\/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma","volume":"164","author":"Fanale","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0165","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1021\/mp300338s","article-title":"Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody\u2013polymer conjugate","volume":"9","author":"Berguig","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.06.010_bb0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-5-64","article-title":"Novel CD20 monoclonal antibodies for lymphoma therapy","volume":"5","author":"Cang","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0175","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0180","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0185","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0190","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0195","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0200","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-0850","article-title":"Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma","volume":"18","author":"Forero-Torres","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0205","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","article-title":"Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0210","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0215","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12185-013-1278-z","article-title":"Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia\/lymphoma","volume":"97","author":"Kato","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0220","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-11-3308","article-title":"Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia","volume":"18","author":"Vitale","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","article-title":"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"20","author":"Ribrag","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0230","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody\u2013drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.06.010_bb0235","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti\u2013IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0240","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","article-title":"Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway","volume":"119","author":"Honeychurch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0245","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0250","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nbt0114-6b","article-title":"Genentech's glyco-engineered antibody to succeed Rituxan","volume":"32","author":"Ratner","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.06.010_bb0260","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0270","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2017.06.010_bb0275","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/CCO.0000000000000108","article-title":"Antibody drug conjugates Curr","volume":"26","author":"Teicher","year":"2014","journal-title":"Opin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0280","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0285","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0290","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.3240341","article-title":"Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically","volume":"240","author":"Zein","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.06.010_bb0295","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/138945010790980376","article-title":"New targets of therapy in T-cell lymphomas","volume":"11","author":"Erter","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2017.06.010_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70010-4","article-title":"Anti-CD22 therapy in acute lymphoblastic leukaemia","volume":"13","author":"Hoelzer","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0305","first-page":"1","article-title":"EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia","author":"Charmsaz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb0310","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2119\/molmed.2015.00210","article-title":"Novel targeted therapy for precursor B-cell acute lymphoblastic leukemia: anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate","volume":"22","author":"Satake","year":"2016","journal-title":"Mol. Med."},{"issue":"1311","key":"10.1016\/j.addr.2017.06.010_bb0315","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.addr.2017.06.010_bb0320","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0325","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.V128.22.896.896","article-title":"ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): final results of the SWOG\/alliance\/ECOG S0535 trial","volume":"128","author":"Lancet","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.addr.2017.06.010_bb0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MOH.0000000000000319","article-title":"What are the most promising new agents in acute myeloid leukemia?","volume":"24","author":"Sallman","year":"2017","journal-title":"Curr. Opin. Hematol"},{"key":"10.1016\/j.addr.2017.06.010_bb0335","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0340","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2014.06.014","article-title":"An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies","volume":"38","author":"Bera","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0345","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","article-title":"IL1RAP antibodies block IL-1\u2013induced expansion of candidate CML stem cells and mediate cell killing in xenograft models","volume":"128","author":"\u00c5gerstam","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0350","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2141.2011.08941.x","article-title":"CD48 as a novel molecular target for antibody therapy in multiple myeloma","volume":"156","author":"Hosen","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0355","first-page":"74","article-title":"Empliciti (elotuzumab): first SLAMF7 antibody therapy approved for the treatment of patients with previously treated multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.addr.2017.06.010_bb0360","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0365","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1538-7445.AM2016-1195","article-title":"Abstract 1195: SGN-CD352A: a novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma","volume":"76","author":"Lewis","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0370","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0375","doi-asserted-by":"crossref","first-page":"4640+","DOI":"10.1172\/JCI85856","article-title":"Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells","volume":"126","author":"Sherbenou","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.addr.2017.06.010_bb0380","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V120.21.728.728","article-title":"Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed\/refractory multiple myeloma (MM)","volume":"120","author":"Berdeja","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0385","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antib2020338","article-title":"Immunotherapy of B-cell lymphoma with an engineered bispecific antibody targeting CD19 and CD5","volume":"2","author":"L\u00fcttgau","year":"2013","journal-title":"Antibodies"},{"key":"10.1016\/j.addr.2017.06.010_bb0390","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0395","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0400","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.leukres.2013.08.007","article-title":"Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells","volume":"37","author":"Tanios","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0405","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1538-7445.AM2016-1042","article-title":"Abstract 1042: development of AEB1102, an engineered human arginase 1 for patients with solid tumors","volume":"76","author":"Rowlinson","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0410","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol. Am. Soc. Hematol Educ. Program"},{"key":"10.1016\/j.addr.2017.06.010_bb0415","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","article-title":"Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation","volume":"109","author":"Qi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.addr.2017.06.010_bb0420","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.chembiol.2013.09.013","article-title":"Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth","volume":"20","author":"Garapaty-Rao","year":"2013","journal-title":"Chem Biol."},{"key":"10.1016\/j.addr.2017.06.010_bb0425","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","article-title":"EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis","volume":"30","author":"Beguelin","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0430","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.addr.2017.06.010_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V122.21.1.1","article-title":"EZH2 and BCL6 cooperate to create the germinal center B-cell phenotype and induce lymphomas through formation and repression of bivalent chromatin domains","volume":"22","author":"Beguelin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0440","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1172\/JCI70626","article-title":"Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis","volume":"123","author":"Caganova","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"22","key":"10.1016\/j.addr.2017.06.010_bb0445","first-page":"839","article-title":"Epigenetic targeting with EZH2 and HDAC inhibitors is synergistic in EZH2 deregulated lymphomas","volume":"128","author":"Lue","year":"2016"},{"key":"10.1016\/j.addr.2017.06.010_bb0450","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0455","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccr.2012.10.016","article-title":"Epigenetic therapy leaps ahead with specific targeting of EZH2","volume":"22","author":"Melnick","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0460","article-title":"CREBBP inactivation promotes the development of HDAC3 dependent lymphomas","author":"Jiang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0465","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0470","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2017.06.010_bb0475","doi-asserted-by":"crossref","first-page":"e28585","DOI":"10.1371\/journal.pone.0028585","article-title":"EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas","volume":"6","author":"Ryan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.06.010_bb0480","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2017.06.010_bb0485","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2017.06.010_bb0490","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.06.010_bb0495","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V126.23.473.473","article-title":"Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin lymphoma (NHL) patients","volume":"126","author":"Ribrag","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0500","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.chembiol.2014.09.017","article-title":"EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation","volume":"21","author":"Bradley","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2017.06.010_bb0505","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsmedchemlett.5b00037","article-title":"EPZ011989, a potent, orally-available EZH2 inhibitor with robust in vivo activity","volume":"6","author":"Campbell","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.addr.2017.06.010_bb0510","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.addr.2017.06.010_bb0515","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrd.2016.256","article-title":"Marked for death: targeting epigenetic changes in cancer","volume":"16","author":"Pfister","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0520","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.devcel.2010.10.005","article-title":"Aberrant epigenetic landscape in cancer: how cellular identity goes awry","volume":"19","author":"Berdasco","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0525","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2\u2032-deoxycytidine (decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0530","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb0535","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V96.12.3847","article-title":"Up-regulation of costimulatory\/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells","volume":"96","author":"Maeda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0540","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2017.06.010_bb0545","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0550","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molimm.2012.12.012","article-title":"Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions","volume":"54","author":"Kopp","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2017.06.010_bb0555","doi-asserted-by":"crossref","first-page":"e27414","DOI":"10.4161\/onci.27414","article-title":"The anticancer effects of HDAC inhibitors require the immune system","volume":"3","author":"West","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2017.06.010_bb0560","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.18632\/oncotarget.7180","article-title":"Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells","volume":"7","author":"Gameiro","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2017.06.010_bb0565","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0570","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0575","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0585","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1158\/1078-0432.CCR-12-3869","article-title":"Molecular pathways: targeting MALT1 paracaspase activity in lymphoma","volume":"19","author":"Fontan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0590","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0595","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.06.010_bb0600","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2017.06.010_bb0605","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.06.010_bb0610","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1470-2045(15)00192-8","article-title":"Ibrutinib promising in subtype of DLBCL","volume":"16","author":"Brower","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0615","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0620","doi-asserted-by":"crossref","first-page":"42232","DOI":"10.18632\/oncotarget.6273","article-title":"Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma","volume":"6","author":"Nagel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2017.06.010_bb0625","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0630","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood-2002-10-3236","article-title":"MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma","volume":"101","author":"Sanchez-Izquierdo","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0635","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","author":"Streubel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0640","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.12057","article-title":"Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma","volume":"93","author":"Dierlamm","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.addr.2017.06.010_bb0645","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0650","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1126\/science.1090769","article-title":"Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase","volume":"302","author":"Ruefli-Brasse","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.06.010_bb0655","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1074-7613(03)00293-0","article-title":"Differential requirement for Malt1 in T and B cell antigen receptor signaling","volume":"19","author":"Ruland","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2017.06.010_bb0660","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","article-title":"MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo","volume":"22","author":"Fontan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0665","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1084\/jem.20091167","article-title":"Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells","volume":"206","author":"Ferch","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0670","doi-asserted-by":"crossref","first-page":"19946","DOI":"10.1073\/pnas.0907511106","article-title":"Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma","volume":"106","author":"Hailfinger","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.06.010_bb0675","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccr.2012.11.002","article-title":"Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL","volume":"22","author":"Nagel","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0680","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0685","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1078-0432.CCR-15-0362","article-title":"Molecular pathways: IDH2 mutations\u2014co-opting cellular metabolism for malignant transformation","volume":"22","author":"Stein","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0690","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1074\/jbc.M114.608497","article-title":"Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule","volume":"290","author":"Deng","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.06.010_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2016.12.017","article-title":"Allosteric mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity","author":"Xie","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.addr.2017.06.010_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.46","article-title":"Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo","author":"Chaturvedi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb0705","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nchembio.1930","article-title":"New IDH1 mutant inhibitors for treatment of acute myeloid leukemia","volume":"11","author":"Okoye-Okafor","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2017.06.010_bb0710","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-10-533604","article-title":"IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition","volume":"125","author":"Kernytsky","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0715","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.06.010_bb0720","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/leu.2014.235","article-title":"Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro","volume":"28","author":"Sarkaria","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb0725","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1208\/s12248-014-9676-6","article-title":"Biodegradable Microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer","volume":"17","author":"Makkouk","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2017.06.010_bb0730","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.toxrep.2016.10.006","article-title":"Genotoxic effects of synthetic amorphous silica nanoparticles in the mouse lymphoma assay","volume":"3","author":"Demir","year":"2016","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.addr.2017.06.010_bb0735","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1016\/j.biomaterials.2014.03.039","article-title":"The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1\/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma","volume":"35","author":"Pradhan","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.06.010_bb0740","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/mt.2013.210","article-title":"Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability","volume":"22","author":"He","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.06.010_bb0745","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1166\/jbn.2014.1625","article-title":"The cellular uptake and cytotoxic effect of silver nanoparticles on chronic myeloid leukemia cells","volume":"10","author":"Guo","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2017.06.010_bb0750","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1016\/j.biomaterials.2013.07.015","article-title":"Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions","volume":"34","author":"Guo","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.06.010_bb0755","doi-asserted-by":"crossref","first-page":"27714","DOI":"10.18632\/oncotarget.4663","article-title":"Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2017.06.010_bb0760","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/mt.2012.94","article-title":"Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-\u03baB activity and tumor growth in murine models of multiple myeloma","volume":"20","author":"Taylor","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.06.010_bb0765","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2014.10.005","article-title":"Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo","volume":"196","author":"Ashley","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.06.010_bb0770","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijpharm.2015.04.072","article-title":"Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles","volume":"489","author":"Danesh","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2017.06.010_bb0775","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","author":"Herold","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0780","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/cncr.23463","article-title":"Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2017.06.010_bb0785","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-07-0251","article-title":"Delivery of 5-aza-2\u2032-deoxycytidine to cells using oligodeoxynucleotides","volume":"67","author":"Yoo","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0790","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1868-7083-5-3","article-title":"Pharmacokinetic and pharmacodynamic analysis of 5-aza-2\u2032-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy","volume":"5","author":"Karahoca","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.addr.2017.06.010_bb0795","first-page":"653","article-title":"Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies","volume":"9","author":"Legut","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2017.06.010_bb0800","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2012.12.009","article-title":"Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion","volume":"331","author":"Vijayaraghavalu","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2017.06.010_bb0805","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.06.010_bb0810","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.06.010_bb0815","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-015-0131-7","article-title":"A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40","volume":"8","author":"Chen","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0820","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1182\/blood-2012-04-426643","article-title":"NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma","volume":"120","author":"Mattarollo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0825","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2014-04-568956","article-title":"An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment","volume":"124","author":"Gibbins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0830","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2014.04.041","article-title":"Development and immunological evaluation of HLA-specific chronic myeloid leukemia polyepitope vaccine in Chinese population","volume":"32","author":"Dong","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2017.06.010_bb0835","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.13245","article-title":"Phase I\/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients","volume":"169","author":"Carmon","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0840","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","article-title":"A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine","volume":"92","author":"Boussif","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2017.06.010_bb0845","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jgm.773","article-title":"Recent advances in rational gene transfer vector design based on poly (ethylene imine) and its derivatives","volume":"7","author":"Neu","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0850","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.addr.2004.09.010","article-title":"DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells","volume":"57","author":"Jilek","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.06.010_bb0855","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nm0398-365","article-title":"Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses","volume":"4","author":"Hedley","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb0860","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia","volume":"8","author":"Klencke","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0865","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/386410a0","article-title":"Biologically erodable microspheres as potential oral drug delivery systems","volume":"386","author":"Mathiowitz","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.06.010_bb0870","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcv.2004.09.013","article-title":"Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses","volume":"31","author":"Wang","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.addr.2017.06.010_bb0875","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1016\/j.biomaterials.2005.03.043","article-title":"Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines","volume":"26","author":"Kasturi","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.06.010_bb0880","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jconrel.2006.04.006","article-title":"Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles","volume":"113","author":"Kasturi","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.06.010_bb0885","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nmat2357","article-title":"Infection-mimicking materials to program dendritic cells in situ","volume":"8","author":"Ali","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2017.06.010_bb0890","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1016\/j.biomaterials.2009.06.001","article-title":"In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA\u2013DNA carrying microparticles to dendritic cells","volume":"30","author":"Singh","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.06.010_bb0895","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2011.06.008","article-title":"An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma","volume":"155","author":"Singh","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.06.010_bb0900","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0905","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies","volume":"128","author":"Hoyos","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166891","article-title":"In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia","volume":"11","author":"Minagawa","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.06.010_bb0915","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","article-title":"Generation of CD19-chimeric antigen receptor modified CD8(+) T cells derived from virus-specific central memory T cells","volume":"119","author":"Terakura","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0920","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0925","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0930","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood.V124.21.382.382","article-title":"CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL","volume":"124","author":"Park","year":"2014","journal-title":"Blood"},{"issue":"14 Supplement","key":"10.1016\/j.addr.2017.06.010_bb0935","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/1538-7445.AM2016-2305","article-title":"Abstract 2305: comparative evaluation of peripheral blood T cells and resultant engineered anti-CD19 CAR T cell products from relapsed\/refractory non-Hodgkin's lymphoma (NHL) patients","volume":"76","author":"Langer","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0940","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb0945","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb0950","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.addr.2017.06.010_bb0955","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb0960","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0965","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V124.21.380.380","article-title":"T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL","volume":"124","author":"Grupp","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0970","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.06.010_bb0975","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0980","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb0985","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-12-3199","article-title":"Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia","volume":"19","author":"Conrad","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2017.06.010_bb0990","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2013.177","article-title":"Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas","volume":"28","author":"Sakamaki","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb0995","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1172\/JCI85795","article-title":"Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma","volume":"126","author":"Cardenas","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.06.010_bb1005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2011-07-368472","article-title":"Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma","volume":"119","author":"Qian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djt007","article-title":"The clinical relevance of cancer cell lines","volume":"105","author":"Gillet","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.addr.2017.06.010_bb1015","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2017.06.010_bb1020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/ten.tec.2016.0404","article-title":"Mimicking the acute myeloid leukemia niche for molecular study and drug screening","volume":"23","author":"Houshmand","year":"2016","journal-title":"Tissue Eng. Part C Methods"},{"key":"10.1016\/j.addr.2017.06.010_bb1025","first-page":"3603","article-title":"Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3-D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells","volume":"10","author":"Nair","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2017.06.010_bb1030","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/bcj.2013.32","article-title":"Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model","volume":"3","author":"Decaup","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.addr.2017.06.010_bb1035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajpath.2013.09.018","article-title":"Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma","volume":"184","author":"Gravelle","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2017.06.010_bb1040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.biomaterials.2015.09.007","article-title":"Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells","volume":"73","author":"Tian","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.06.010_bb1045","article-title":"Lymph node stiffness mimicking hydrogels regulate human B cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner","author":"Apoorva","year":"2017","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2017.06.010_bb1050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/ten.tec.2013.0490","article-title":"Patient-specific 3D microfluidic tissue model for multiple myeloma","volume":"20","author":"Zhang","year":"2014","journal-title":"Tissue Eng. Part C Methods"},{"key":"10.1016\/j.addr.2017.06.010_bb1055","series-title":"AACR","author":"de la Puente","year":"2015"},{"key":"10.1016\/j.addr.2017.06.010_bb1060","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","article-title":"Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model","volume":"124","author":"Reagan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1065","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12643","article-title":"A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications","volume":"7","author":"Jakubikova","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2017.06.010_bb1070","first-page":"67","article-title":"Characterization of multiple myeloma clonal cell expansion and stromal Wnt\/\u03b2-catenin signaling in hyaluronic acid-based 3D hydrogel","volume":"28","author":"Narayanan","year":"2014","journal-title":"In Vivo"},{"key":"10.1016\/j.addr.2017.06.010_bb1075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jbiotec.2010.03.001","article-title":"Immunological substance testing on human lymphatic micro-organoids in vitro","volume":"148","author":"Giese","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.addr.2017.06.010_bb1080","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2014-07-587337","article-title":"Integrin alphavbeta3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells","volume":"125","author":"Cayrol","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.addr.2017.06.010_bb1085","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbm.a.36031","article-title":"Lymph node stiffness mimicking hydrogels regulate human B cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner","volume":"105","author":"Apoorva","year":"2017","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2017.06.010_bb1090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOH.0000000000000356","article-title":"Creating artificial lymphoid tissues to study immunity and hematological malignancies","volume":"24","author":"Shah","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb1095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.actbio.2017.01.075","article-title":"Cellular self-assembly and biomaterials-based organoid models of development and diseases","volume":"53","author":"Shah","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2017.06.010_bb1100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.biomaterials.2017.03.015","article-title":"Biomaterials innovation for next generation ex vivo immune tissue engineering","volume":"130","author":"Singh","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.06.010_bb1105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1139\/bcb-2015-0009","article-title":"Anti-CD20 single chain variable antibody fragment\u2013apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas","volume":"93","author":"Crosby","year":"2015","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.addr.2017.06.010_bb1110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2174\/15665232113136660029","article-title":"Antibody-directed double suicide gene therapy targeting of MUC1-positive leukemia cells in vitro and in vivo","volume":"13","author":"Dong","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2017.06.010_bb1115","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.24272","article-title":"Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Ansell","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb1125","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1992.10.2.210","article-title":"Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure","volume":"10","author":"Longo","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/10428199609054778","article-title":"Vinorelbine: a new promising drug in Hodgkin's disease","volume":"22","author":"Devizzi","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.addr.2017.06.010_bb1140","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1145","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb1155","series-title":"ASCO Meeting Abstracts","first-page":"24","article-title":"Rituximab, gemcitabine and oxaliplatin (R-GEMOX): an effective regimen for relapsed and refractory B-cell lymphoma","author":"El Gnaoui","year":"2006"},{"key":"10.1016\/j.addr.2017.06.010_bb1160","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1\u20132 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.addr.2017.06.010_bb1165","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1170","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ajh.24200","article-title":"Follicular lymphoma: 2015 update on diagnosis and management","volume":"90","author":"Freedman","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb1175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/CCO.0b013e328358f62d","article-title":"Current treatment of acute myeloid leukemia","volume":"24","author":"Roboz","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1185","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2017.06.010_bb1190","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.critrevonc.2011.01.014","article-title":"Treatment of acute lymphoblastic leukemia in adults","volume":"81","author":"Narayanan","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb1200","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1200\/jco.2008.26.15_suppl.7019","article-title":"Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL)","volume":"26","author":"Thomas","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1205","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/sj.leu.2400861","article-title":"The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia","volume":"11","author":"Koller","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb1210","first-page":"637","article-title":"Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)","volume":"4","author":"Hiddemann","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2017.06.010_bb1215","first-page":"83","article-title":"Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults","volume":"65","author":"Yap","year":"1980","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.addr.2017.06.010_bb1220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1097-0142(19890701)64:1<16::AID-CNCR2820640104>3.0.CO;2-O","article-title":"Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia","volume":"64","author":"Kantarjian","year":"1989","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2017.06.010_bb1225","first-page":"83","article-title":"Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults","volume":"65","author":"Yap","year":"1981","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.addr.2017.06.010_bb1230","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1235","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb1240","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7073","article-title":"ENESTnd 5-year update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM)","author":"Larson","year":"2014","journal-title":"Proc. Am. Soc. Clin. Oncol. Date of presentation:"},{"key":"10.1016\/j.addr.2017.06.010_bb1245","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1250","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb1255","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2017.06.010_bb1260","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1265","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2017.06.010_bb1270","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1275","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood.V116.21.697.697","article-title":"Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study","volume":"116","author":"Hillmen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1280","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb1285","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.06.010_bb1295","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1300","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial","volume":"23","author":"Elter","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1305","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2017.06.010_bb1315","series-title":"Seminars in Hematology","first-page":"S3","volume":"vol. 42","author":"Anderson","year":"2005"},{"key":"10.1016\/j.addr.2017.06.010_bb1320","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V110.11.450.450","article-title":"VELCADE\/dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 trial","volume":"110","author":"Harousseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1325","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood.V84.12.4278.bloodjournal84124278","article-title":"Early myeloablative therapy for multiple myeloma","volume":"84","author":"Alexanian","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.06.010_bb1330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2007.0015","article-title":"The emerging role of novel therapies for the treatment of relapsed myeloma","volume":"5","author":"Richardson","year":"2007","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.addr.2017.06.010_bb1335","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X17300947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X17300947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T08:45:24Z","timestamp":1602319524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X17300947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":265,"alternative-id":["S0169409X17300947"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2017.06.010","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug discovery and therapeutic delivery for the treatment of B and T cell tumors","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2017.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}